Investigating the optimal size of anticancer nanomedicine
Nanomedicines (NMs) offer new solutions for cancer diagnosis and therapy. However, extension of progression-free interval and overall survival time achieved by Food and Drug Administration-approved NMs remain modest. To develop next generation NMs to achieve superior anticancer activities, it is crucial to investigate and understand the correlation between the physicochemical properties of NMs (particle size in particular) and their interactions with biological systems to establish criteria for NM optimization. Here, we systematically evaluated the size-dependent biological profiles of three monodisperse drug-silica nanoconjugates (NCs; 20, 50, and 200 nm) through both experiments and mathematical modeling and aimed to identify the optimal size for the most effective anticancer drug delivery. Among the three NCs investigated, the 50-nm NC shows the highest tumor tissue retention integrated over time, which is the collective outcome of deep tumor tissue penetration and efficient cancer cell internalization as well as slow tumor clearance, and thus, the highest efficacy against both primary and metastatic tumors in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 111(2014), 43 vom: 28. Okt., Seite 15344-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tang, Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7631-86-9 |
|---|
| Anmerkungen: |
Date Completed 17.04.2015 Date Revised 31.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.1411499111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM242796796 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM242796796 | ||
| 003 | DE-627 | ||
| 005 | 20231224131152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.1411499111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0809.xml |
| 035 | |a (DE-627)NLM242796796 | ||
| 035 | |a (NLM)25316794 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigating the optimal size of anticancer nanomedicine |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2015 | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Nanomedicines (NMs) offer new solutions for cancer diagnosis and therapy. However, extension of progression-free interval and overall survival time achieved by Food and Drug Administration-approved NMs remain modest. To develop next generation NMs to achieve superior anticancer activities, it is crucial to investigate and understand the correlation between the physicochemical properties of NMs (particle size in particular) and their interactions with biological systems to establish criteria for NM optimization. Here, we systematically evaluated the size-dependent biological profiles of three monodisperse drug-silica nanoconjugates (NCs; 20, 50, and 200 nm) through both experiments and mathematical modeling and aimed to identify the optimal size for the most effective anticancer drug delivery. Among the three NCs investigated, the 50-nm NC shows the highest tumor tissue retention integrated over time, which is the collective outcome of deep tumor tissue penetration and efficient cancer cell internalization as well as slow tumor clearance, and thus, the highest efficacy against both primary and metastatic tumors in vivo | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a mathematical model | |
| 650 | 4 | |a nanomedicine | |
| 650 | 4 | |a silica nanoparticle | |
| 650 | 4 | |a size effect | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Nanoconjugates |2 NLM | |
| 650 | 7 | |a Silicon Dioxide |2 NLM | |
| 650 | 7 | |a 7631-86-9 |2 NLM | |
| 700 | 1 | |a Yang, Xujuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Kaimin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhury, Isthier |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Mincheol |e verfasserin |4 aut | |
| 700 | 1 | |a Hartman, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Dobrucki, Iwona T |e verfasserin |4 aut | |
| 700 | 1 | |a Dobrucki, Lawrence W |e verfasserin |4 aut | |
| 700 | 1 | |a Borst, Luke B |e verfasserin |4 aut | |
| 700 | 1 | |a Lezmi, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Helferich, William G |e verfasserin |4 aut | |
| 700 | 1 | |a Ferguson, Andrew L |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Timothy M |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Jianjun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 111(2014), 43 vom: 28. Okt., Seite 15344-9 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2014 |g number:43 |g day:28 |g month:10 |g pages:15344-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.1411499111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2014 |e 43 |b 28 |c 10 |h 15344-9 | ||